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Docosahexaenoic acid (DHA) is an essential ω-3 long-chain polyunsaturated fatty acid
(LCPUFA) and represents the dominant structural fatty acid in the retina and in the brain’s
graymatter. Due to its active participation in the development of the nervous system, DHA
is one of the most studied LCPUFA and is currently considered a critical nutrient during
pregnancy and breastfeeding. Increasing evidence in literature suggests that an adequate
concentration of DHA is required from the fetal stage through to early life to ensure
optimal neurological development. Likewise, many studies in literature demonstrated
that an adequate supply of DHA during pregnancy and lactation is essential to promote
proper brain development in utero and in early life. Daily supplementation of DHA in
newborns has potentially stronger effects compared to maternal supplementation during
pregnancy. Supplementation initiated in the second year of life in children born preterm
did not result in global cognitive development improvements. Preliminary findings arising
from metabolomics has reported that mother’s milk and infant formula supplementation
of Vitamin D associated with DHA results in a higher antioxidant and protective action,
with a possible positive influence on renal function and body fat on preterm infants
compared to those receiving only vitamin D. Recent applications of metabolomic studies
on newborns may lead to a better understanding of the metabolic process linked to
early nutrition and, subsequently, to the development of targeted and personalized
nutritional strategies.
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INTRODUCTION
Docosahexaenoic acid (DHA, C22:6n−3) is an essential ω-3 long-chain polyunsaturated fatty acid
(LCPUFA) and represents the dominant structural fatty acid in the retina and in the brain’s gray
matter (1). DHA accounts for 50% of the total brain lipids and between 60 and 80% of the brain
membrane phospholipids (2) and is the most abundant n−3 LCPUFA in the nervous system (NS).
In literature, its function has been shown as crucial for neurogenesis and synaptogenesis, taking an
important role in neurotransmitter function, signal transduction, gene expression, neurogenesis,
and anti-inflammation (3). Due to its involvement in the development of NS, DHA is one of
the most studied LCPUFA and is currently considered a critical nutrient during pregnancy and
breastfeeding (4).
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Pregnancy
The development of the NS starts in utero and proceeds until
the postnatal period. During the last trimester of pregnancy,
the so-called “brain growth spurt” takes place, i.e., a period
in which the brain’s growth is very fast, and its composition
quickly changes (5). DHA is integrated into brain and retinal
cell membranes in the third trimester of pregnancy and the
first two years of life (6). During pregnancy, LCPUFAs needs
for the fetus are elevated and mainly satisfied by the placenta,
with only a little amount synthesized into the fetus (7). For
this reason, the concentration of fetal DHA is correlated to
the amount of DHA ingested by the mother (8). Adequate
nutrition during pregnancy is thus essential, and maternal DHA
intake during pregnancy is associated with the child’s neuro-
developmental performance (9, 10). Reports in literature have
shown how women from Western countries consume diets
that are low in DHA, which is almost exclusively present in
seafood and accumulates throughout the marine food chain from
sources such as microalgae (11). Moreover, pregnant women
could reduce their consumption of certain species of deep-sea
predatory fish due to the potential presence of heavy metals like
mercury, lead, and cadmium (3). Literature data suggest that only
a small quantity of DHA can be synthesized in the body from α-
linolenic acid (ALA), a shorter chain omega-3 fatty acid that can
be found in many vegetables and plants commonly eaten (12).
Docosahexaenoic acid supplementation in the prenatal period
has also been associated with a decreased incidence of allergic
diseases in infants (13). A report published in 2013 by Kuratko
et al. (14) demonstrated that a supplement of 600mg DHA/d
in the last half of gestation resulted in overall greater gestation
duration, with reduction in early preterm and very-low birth
weight (VLBW) births (14). One mechanism by which DHA
may decrease the incidence of preterm birth is by decreasing
prostaglandin E2 and prostaglandin F2α production, thereby
reducing inflammation within the uterus, which is a risk factor
for preterm birth (15).
In a recent article published by Feltham et al. (16) DHA
supplementation in pregnant women was reported to have a
potential role in combating prenatal alcohol-induced insults on
brain development.
The above findings suggest that it is necessary to promote
supplementation with DHA during pregnancy and lactation
through consuming products rich in DHA, such as fish oil, krill
oil capsules, or food fortified with n−3 LCPUFA (17). While
in the intra-uterine life the availability of DHA for the infant
is directly related to transfer through the placenta, after birth it
depends on transfer through lactation (18).
Lactation
Human milk is a common and natural source of LCPUFA
and DHA.
PUFA concentration in human milk is relatively stable.
DHA concentration shows a decrease (approximately from 0.5%
colostrum to 0.25% mature milk) according to the stage of
lactation (19–21). DHA levels in HM are also influenced by
gestational pathologies. Three studies evaluated the fatty acid
composition of the HM of Preeclamptic mothers (PE). Fares et al.
(22) evaluated the total fatty acid profile of colostrum in mothers
who delivered preterm and found lower DHA levels and higher
Arachidonic Acid (AA) levels, AA:DHA, and ω6:ω3 ratios in the
PE group. Dangat et al. (23, 24) published two studies focused
on long chain polyunsaturated fatty acids. The first study shows
that DHA and nervonic acid concentrations were higher in the
colostrum of the PE group, as compared to the normotensive
control group. The second study shows that DHA concentrations
were also higher at day 3, and at 1.5 and 3.5 months (23).
The DHA level of human milk varies widely across different
countries and regions; a possible factor contributing to this
difference is the diet. The DHA levels range between 0.17 and
0.99% of total fatty acids, with the lowest levels reported for both
Canada and the United States and the highest levels in Japan.
High levels (0.74% of total fatty acids) were also reported for
the Philippines. A 2007 review by Brenna et al. reported that “a
mean DHA human milk level of 0.32% (25). For DHA, the lowest
value (0.06%) was reported for Pakistan, but similar low values
were observed in rural South Africa (0.1%) and Canada (0.12%),
whereas the highest values were reported for the Canadian Arctic
(1.4%) and Japan (1.1%).”
The latest research from Fu et al. (26) and Sánchez-Hernández
et al. (27) assessed that: “the DHA and arachidonic acid (AA)
levels in human milk (vary) according to country and region,
reporting similar values (0.42% for DHA and 0.71% for AA).”
Literature data often report that n−3 fatty acids such as DHA
are modulated by diet whereas n6 fatty acids, like ARA, are
not (28).
Breastfeeding women need to consume a daily DHA intake of
200mg to produce milk with a DHA content of at least 0.3%. This
DHA concentration is required for a breastfed infant to obtain
the daily DHA supply considered desirable to meet metabolic
needs (100mg DHA/day) (29). In recent years, milk companies
have started to enrich infant formulas with DHA, but literature
data suggest that DHA supplementation may be associated with
either better outcomes or with no effect in infants fed artificially.
This probably depends on DHA levels in formulas, on the co-
presence of Arachidonic acid (ARA), on infant DHA status at
birth, and on the infant’s genetic background (9). On the other
hand, neonates fed with enriched formula have a lower incidence
of infections and allergic/atopic diseases in early stages of life,
compared to exclusively breast-fed infants (30).
Neonatal Period
Preterm infants, especially those born very preterm, do not have
the opportunity to accumulate DHA during most of the last
trimester of pregnancy due to a shortened gestation (31).
During neonatal life, preterm infants require more nutrients
to ensure the maturation and development of tissues and organs.
LCPUFA needs are also higher (7). Furthermore, enzymes
responsible for the endogen synthesis of DHA in preterm
newborns have low activity (32). Consequently, preterm infants
are disadvantaged compared to term infants for access to
the DHA needed for brain maturation. This factor exposes
these infants to a higher risk of neonatal morbidities (7).
Several studies demonstrated that DHA daily supplementation
begun in the neonatal period improves global developmental
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outcomes in preterm infants. Moreover, recent studies show
that higher circulating DHA levels in premature infants are
related to better vision and neurodevelopmental outcomes
(33). High DHA levels also correlate with a lower risk of
necrotizing enterocolitis (34), retinopathy of prematurity (35),
and bronchopulmonary dysplasia.
The metabolomics approach has been recently applied in
a study investigating the dynamic variations in the urinary
metabolic profiles of two groups of preterm infants receiving
different supplementation strategies (36). Supplementation was
focused on increasing DHA and vitamin D content in mother’s
milk or infant formula over a period of two months after hospital
discharge. The first group of preterm newborns received only 400
I.U./day of vitamin D (DS), whereas the second group received a
supplementation of vitamin D enriched with 20 mg/day of DHA
(D-DHAS). In this study, significant differences between the two
types of supplementation came to light. Interestingly, compared
to the DS group, the D-DHAS group exhibited more abundant
urine levels of betaine, creatinine, N, NDMG, and DMA, and a
lower content of myo-inositol and lactate (36). Researchers found
that lower values of myo-inositol and lactate in urine are related
to lower cellular and organism stress, especially for the brain
(37), while N,N-DMG protects the neurodevelopment and the
neuronal cell function thanks to its antioxidant function (37). In
an animal study onDMA, a product of cholinemetabolism by the
gut microbiota is reported to be inversely correlated with body
fat (38). The increasing rate of urinary excretion of creatinine,
which in previous studies has been positively correlated with
weight, height, and postconceptional age, can also be associated
with the maturation of infants’ renal functions (39). Betaine
is synthesized by choline dehydrogenase and betaine aldehyde
dehydrogenase in the gut mucosa, liver, and kidney (40). It is
widely recognized as an osmolyte or methyl group donator to
homocysteine to form methionine and S-adenosylmethionine,
promoting remethylation (41).
Overall, the results of this study suggest higher antioxidant
and protective action by supplementation with DHA and vitamin
D compared to those with only vitamin D and a possible positive
influence on renal function and body fat composition (41).
The current standard of supplementation in preterm
newborns is enteral feeding and the standard dietary provision
of DHA is based on the average worldwide content found in
human milk (4), which is 0.3% of total milk fatty acid (4, 42).
Regardless, formula or breast milk DHA supplementation
remains dependent on the infant’s ability to tolerate full
volume enteral feedings, and the optimal dose and method of
administration is still unknown (42). A randomized clinical
trial published in 2018 by Keim et al. (43) reported that DHA
daily supplementation did not result in improvements in
cognitive development in preterm newborns if started only in
the second year of life. The meta-analysis conducted in 2018
by Shulkin reviewed the randomized controlled trials of n−3
PUFA supplementation in mothers or infants (age ≤ 2 years)
and evaluated standardized measures of cognitive or visual
development up to 18 years of age. The authors found that
n−3 PUFA supplementation improves visual acuity and MDI in
preterm infants, without statistically significant effects on PDI or
IQ in different intervention period subgroups (6).
DISCUSSION AND CONCLUSION
Increasing evidence in the literature suggests that an adequate
concentration of DHA is required from the fetal stage to early
life to ensure optimal neurological development.
Docosahexaenoic acid supplementation is reported to have
benefits on pregnancy outcomes; therefore, pregnant women
should be supported to achieve a DHA intake of 600mg daily in
the last trimester of pregnancy.
The third trimester experiences the highest DHA
accumulation, and premature infants are therefore at risk
of DHA deficiency due to a shortened gestation. For this reason,
they should receive a diet with at least 0.3% DHA (4), but further
trials are necessary to determine the optimal dose and route of
administration of DHA in newborns.
Daily supplementation of DHA in newborns has potentially
stronger effects compared to maternal supplementation during
pregnancy. In children born preterm, supplementation initiated
only in the 2nd year of life did not result in a global cognitive
development improvement.
Preliminary findings arising from metabolomics suggest that
mother’s milk and infant formula supplementation of Vitamin
D associated with 400 I.U./day of DHA result in a higher
antioxidant and protective action compared to those receiving
only vitamin D. A potential positive influence on renal function
and body fat on preterm infants was also found. Recent
applications of metabolomic studies on newborns may lead to
a better understanding of the metabolic processes linked to
early nutrition and, subsequently, to developing targeted and
personalized nutritional strategies.
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